JNJ-78934804

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Crohn's DiseaseCrohn DiseaseColitis, Ulcerative

74 competitors in Crohn's Disease

#DrugCompanyPhaseTrials

1

Remicade

Johnson & Johnson

Approved

282

Entyvio

Takeda

Approved

133

Omvoh

Eli Lilly

Approved

84

Trexall

Jazz Pharmaceuticals

Approved

15

Lamprene

Novartis

Approved

—6

Calciferol

Jazz Pharmaceuticals

Approved

—7

Levulan

Sun Pharmaceutical Industries, Inc.

Approved

—8

Mycobutin

Pfizer

Approved

—9

Opzelura

Pfizer

Approved

—10

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4Show 41 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Colitis, Ulcerative2 trials

A Phase 3 Randomized, Double-blind, and Active Controlled, Multi-center Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting·Johnson & Johnson·Phase 3·NCT07577856·644 enrolled

A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting·Johnson & Johnson·Phase 2·NCT05242484·577 enrolled

Crohn Disease1 trial

A Phase 3, Randomized, Double-blind, and Active-controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

Recruiting·Johnson & Johnson·Phase 3·NCT07577843·460 enrolled

Crohn's Disease1 trial

A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

Active, not recruiting·Johnson & Johnson·Phase 2·NCT05242471·703 enrolled

Details

Drug Info

Related News